Hua Bian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1652587/publications.pdf

Version: 2024-02-01

304743 395702 1,266 39 22 33 citations h-index g-index papers 45 45 45 1778 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radical Biology and Medicine, 2019, 141, 192-204.	2.9	147
2	Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. British Journal of Pharmacology, 2018, 175, 374-387.	5.4	116
3	NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Frontiers in Pharmacology, 2019, 10, 877.	3.5	86
4	Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2020, 36, e3292.	4.0	68
5	Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. Journal of Translational Medicine, 2016, 14, 266.	4.4	67
6	FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 150-162.	3.7	51
7	Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression. Lipids in Health and Disease, 2018, 17, 114.	3.0	49
8	Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine, 2021, 66, 103290.	6.1	47
9	The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Molecules, 2016, 21, 1336.	3.8	45
10	The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women. Journal of Translational Medicine, 2016, 14, 11.	4.4	39
11	DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metabolism, 2021, 33, 2004-2020.e9.	16.2	38
12	Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in dietâ€induced insulinâ€resistant mice. Hepatology, 2018, 68, 1361-1375.	7.3	37
13	Effects of dietary interventions on liver volume in humans. Obesity, 2014, 22, 989-995.	3.0	34
14	Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. BMC Medicine, 2020, 18, 144.	5.5	33
15	Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. EBioMedicine, 2020, 57, 102849.	6.1	33
16	CREBZF as a Key Regulator of STAT3 Pathway in the Control of Liver Regeneration in Mice. Hepatology, 2020, 71, 1421-1436.	7.3	32
17	Impact of Type 2 Diabetes on Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Endocrine Practice, 2020, 26, 444-453.	2.1	31
18	Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. Clinical Nutrition, 2018, 37, 1752-1758.	5.0	30

#	Article	IF	CITATIONS
19	Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease. Journal of Proteome Research, 2021, 20, 2340-2351.	3.7	27
20	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0160526.	2.5	26
21	Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases. Obesity, 2015, 23, 1929-1937.	3.0	25
22	The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Diabetologia, 2019, 62, 644-654.	6.3	22
23	Osteocalcin and Non-Alcoholic Fatty Liver Disease: Lessons From Two Population-Based Cohorts and Animal Models. Journal of Bone and Mineral Research, 2020, 36, 712-728.	2.8	22
24	Increased Liver Fat Content and Unfavorable Glucose Profiles in Subjects Without Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 149-155.	4.4	21
25	Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. BMJ Open Diabetes Research and Care, 2020, 8, e000999.	2.8	20
26	Serum retinol binding protein 4 is associated with visceral fat in human with nonalcoholic fatty liver disease without known diabetes: a cross-sectional study. Lipids in Health and Disease, 2015, 14, 28.	3.0	18
27	Impact of nonâ€elcoholic fatty liver disease on liver volume in humans. Hepatology Research, 2015, 45, 210-219.	3.4	16
28	Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids in Health and Disease, 2021, 20, 126.	3.0	15
29	FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c. Lipids in Health and Disease, 2019, 18, 197.	3.0	14
30	Acute Effects of Sleeve Gastrectomy on Glucose Variability, Glucose Metabolism, and Ghrelin Response. Obesity Surgery, 2021, 31, 4005-4014.	2.1	10
31	Preoperative Thyroid Autoimmune Status and Changes in Thyroid Function and Body Weight After Bariatric Surgery. Obesity Surgery, 2019, 29, 2904-2911.	2.1	8
32	Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. Frontiers in Medicine, 2021, 8, 637652.	2.6	8
33	Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease. Lipids in Health and Disease, 2021, 20, 27.	3.0	8
34	Serum retinol binding protein 4 is negatively related to estrogen in Chinese women with obesity: a cross-sectional study. Lipids in Health and Disease, 2016, 15, 52.	3.0	7
35	Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes. Journal of Translational Medicine, 2021, 19, 393.	4.4	6
36	Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. BMJ Open Diabetes Research and Care, 2020, 8, e001311.	2.8	3

Hua Bian

#	Article	IF	CITATION
37	DS21, a new noninvasive technology, is effective and safe for screening for prediabetes and diabetes in Chinese population. BioMedical Engineering OnLine, 2020, 19, 78.	2.7	2
38	Promotion of nonalcoholic steatohepatitis by RNA N6-methyladenosine reader IGF2BP2 in mice. , 2022, 1, $161-174$.		2
39	Investigation of Daily Glucose Profile of Inpatients in Non-endocrinology Departments in Chinese Population. Frontiers in Public Health, 2020, 8, 521227.	2.7	0